Trametinib: First global approval

Drugs

Volumn 73, Issue 11, 2013, Pages 1245-1254

  Wright, Cameron J M ^a   McCormack, Paul L ^b  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AFURESERTIB; B RAF KINASE; DABRAFENIB; DACARBAZINE; DOCETAXEL; EVEROLIMUS; FENOFIBRATE; GEMCITABINE; MEKINIST; PACLITAXEL; PANITUMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ACNE; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; BONE MARROW SUPPRESSION; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL SEROUS RETINOPATHY; CHILL; CHORIORETINOPATHY; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART EJECTION FRACTION; HEART VENTRICLE FUNCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEUKEMIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MELANOMA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL EDEMA; QUALITY OF LIFE; RETINA VEIN OCCLUSION; SALIVARY GLAND CANCER; SIDE EFFECT; SKIN TOXICITY; STEADY STATE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANOMA; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES;

EID: 84880780573     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0096-1     Document Type: Article

References (35)

1. American Cancer Society. Cancer facts and figures 2013; 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-036845.pdf (Accessed 14 Jun 2013).
2. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014-23.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.
4. Johnson DB, Sosman JA. Update on the targeted therapy of melanoma. Curr Treat Options Oncol. 2013;14(2):280-92.
5. GlaxoSmithKline. Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist(Tm) (trametinib) tablets, approved by FDA as single-agent therapies [media release]; 29 May 2013. http://www.gsk.com/media/press-releases/2013/two-new-gsk-oral- oncology-treatments-braf-inhibitor-tafinlar-.html.
6. US FDA. Mekinist (trametinib) tablets: prescribing information; 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204114s000lbl.pdf (Accessed 14 Jun 2013).
7. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31(4):482-9.
8. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-14.
9. GlaxoSmithKline. GSK announces European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma [media release]; 7 Feb 2013. http://www.gsk.com/media/press-releases/2013/Regulatory-update-European- submission-MEK-monotherapy-BRAF-MEK-combination-therapy-metastatic-melanoma. html.
10. GlaxoSmithKline. GlaxoSmithKline starts phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery [media release]; 1 Feb 2013. http://www.gsk.com/media/press-releases/2013/ glaxosmithkline-starts-phase-iii-study-to-test-combined-braf-mek.html.
11. GlaxoSmithKline. GSK announces start of phase III programme for combination of dabrafenib (GSK2118436) and trametinib (GSK1120212) in BRAF V600 mutation-positive metastatic cutaneous melanoma [media release]; 29 May 2012. http://www.gsk.com/media/press-releases/2012/gsk-announces-start-of-phase-iii- programme-for-combination-of-dabrafenib-gsk2118436-and-trametinib-gsk1120212-in- braf-v600-mutation-positive-metastatic-cutaneous-melanoma.html.
12. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-703.
13. Japan Tobacco. Japan Tobacco, GlaxoSmithKline conclude licensing agreement for new drug candidate [media release]; 20 Apr 2006. http://www.japancorp.net.
14. Yoshida T, Kakegawa J, Yamaguchi T, et al. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. Oncotarget. 2012;3(12):1533-45.
15. Stones CJ, Kim JE, Joseph WR, et al. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet. 2013;4:66.
16. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249-56.
17. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212 [abstract no. 2503]. J Clin Oncol. 2010;28(15 Suppl. 1).
18. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225-31.
19. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012;11(4):909-20.
20. Carlino MS, Gowrishankar K, Saunders CA, et al. Anti-proliferative effects of continued MAPK pathway inhibition following acquired resistance to dabrafenib and trametinib: implications for melanoma treatment beyond progression [abstract]. Pigment Cell Melanoma Res. 2012;25(6):846-7.
21. Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010;102(12):1724-30.
22. Morris EJ, Jha S, Restaino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013. doi: 10.1158/2159-8290.CD-13-0070.
23. Andrews M, Behren A, Chiohn F, et al. Colorectal cancer promoted in a melanoma patient receiving dabrafenib (GSK2118436) in combination with MEK1/2 inhibitor trametinib (GSK1120212) [abstract]. Pigment Cell Melanoma Res. 2012;25(6):842.
24. Walters DM, Lindberg JM, Adair SJ, et al. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia (New York). 2013;15(2):143-55.
25. Watanabe M, Sowa Y, Yogosawa M, et al. Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells. Cancer Sci. 2013;104(6):687-93.
26. Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):773-81.
27. Kassir N, Mouksassi M, Cox DS, et al. Population pharmacokinetics (PK) of trametinib (GSK1120212), a MEK inhibitor, in subjects with cancer [abstract no. PII-48]. Clin Pharmacol Ther. 2013;93 Suppl. 1:S69.
28. Cox DS, Fang L, Bauman JW, et al. The effect of food on the single dose pharmacokinetics of a novel MEK inhibitor, trametinib, in subjects with solid tumors [abstract no. PI-49]. Clin Pharmacol Ther. 2013;93 Suppl. 1:S31-2.
29. Infante JR, Patnaik A, Jones SF, et al. A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: interim results [abstract no. B128]. Mol Cancer Ther. 2011;10(11 Suppl. 1).
30. Schadendorf D, Milhem M, Demidov LV, et al. Trametinib (T) vs chemotherapy (C) in patients with BRAF V600E+ metastatic melanoma (MM): quality of life (QOL) analysis [abstract]. Pigment Cell Melanoma Res. 2013;26(1):154.
31. Falchook G, Infante JR, Fecher LA, et al. The oral MEK 1/2 inhibitor GSK1120212 demonstrates early efficacy signals [abstract no. 4847]. 35th Congress of the European Society for Medical Oncology, 8-12 Oct 2010;Milan.
32. Infante JR, Papadopoulos KP, Bendell JC, et al. A phase 1b study of trametinib, an oral mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur J Cancer. 2013;49(9):2077-85.
33. Grilley-Olson JE, Bedard P, Fasolo A, et al. A phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K/mTOR inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors [abstract no. B155]. AACR Molecular Targets and Cancer Therapeutics, 12-16 Nov 2011;San Francisco.
34. Corcoran RB, Falchook GS, Infante JR, et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212) [abstract no. 3528]. J Clin Oncol. 2012;30(15 Suppl. 1).
35. Borthakur G, Popplewell L, Boyiadzis M, et al. Phase I/II trial of the MEK1/2 inhibitor trametinib (GSK1120212) in relapsed/refractory myeloid malignancies: evidence of activity in patients with RAS mutation-positive disease [abstract no. 677]. Blood. 2012;120(21).